Op2Lysis — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Op2Lysis is a clinical-stage biotech targeting hemorrhagic stroke, a condition with high mortality and disability rates and no approved pharmacological therapy. The company's core innovation is the NANOp2Lysis® platform, which combines a novel engineered tissue plasminogen activator (OptPA) with a nanoparticle-based delivery system to enhance safety and efficacy in clot dissolution. With a strong founding team combining deep industry development and neurovascular research expertise, and backed by European grants like the EIC Accelerator, Op2Lysis is advancing O2L-001 through preclinical development toward clinical trials.

Hemorrhagic StrokeCerebrovascular Disease

Technology Platform

NANOp2Lysis® platform: a nanoparticle-based drug delivery system combined with an engineered thrombolytic agent (OptPA) designed for safer, more effective clot and hematoma dissolution in the brain.

Opportunities

The primary opportunity is addressing the massive unmet medical need in hemorrhagic stroke, where no pharmacological therapy exists, representing a potential multi-billion dollar market.

Success with O2L-001 would validate the NANOp2Lysis® platform, enabling expansion into other thrombotic indications like ischemic stroke or deep vein thrombosis.

Support from the EIC Accelerator and alignment with European public health goals provides financial and strategic tailwinds.

Risk Factors

The key risks are high clinical development risk as the novel therapy moves from preclinical models to humans, and significant regulatory risk in gaining approval for a first-in-class treatment in a severe indication.

The company also faces financial risk dependent on securing further capital to fund expensive clinical trials, and competition from other entities developing alternative hemorrhagic stroke interventions.

Competitive Landscape

The competitive landscape for hemorrhagic stroke therapy includes companies developing minimally invasive surgical devices (e.g., Nico Corp, Penumbra) and other pharmacological approaches targeting clot resolution or neuroprotection (e.g., BioAxone's BA-1049, Remedy's cisternal lavage). Op2Lysis differentiates itself with a combined pharmacological (OptPA) and delivery (nanoparticle) approach aimed at systemic administration with improved safety, potentially offering wider accessibility than surgical options.

More companies in Biologics / Biosimilars →More companies in France →